Targeting Fibrinolytic Agents to the Vessel Wall: A New Therapeutic Niche?

• References

• 1 Smith RA G, Dupe RJ, English PD, Green J. Fibrinolysis with acyl enzymes: a new approach to thrombolytic therapy. Nature (London) 1981; 290: 505-8
• 2 Little SP, Bang NU, Harms CS, Marks CA, Mattler LE. Functional properties of carbohydrate depleted tissue plasminogen activator. Biochemistry 1984; 23: 6191-5
• 3 Flohe L. Single chain urokinase type plasminogen activators: new hopes for clot-specific lysis. Eur Heart J 1985; 6: 905-8
• 4 Bode C, Matsucda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent: a specific fibrinolytic agent. Science 1985; 229: 765-7
• 5 Collcn D, Dewerchin M, Stassen JM, Kicckcns L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase type plasminogen activator with a monoclonal antibody specific for cross linked fibrin. Fibrinolysis 1989; 3: 197-202
• 6 Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-6
• 7 Hajjar KA, Hamel NM. Identification and characterisation of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990; 2165: 2908-16
• 8 Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and type plasminogen activators. J Cell Biol 1982; 94: 631-6
• 9 Davies MJ, Richardson PD, Woolf N, Katz MannJ Dr. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage and smooth muscle cell content. Br Heart J 1993; 69: 37-82
• 10 Underwood MJ, de Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price?. Cardiovasc Res 1993; 69: 377-81
• 11 Underwood MJ, More RS, Wcerasena N, de Bono DP. The effect of surgical preparation and in-vitro distension on the intrinsic fibrinolytic activity of saphenous vein. Eur J Vase Surg 1993; 7: 21-5
• 12 Assad-Mosel JL, Frye RI, Connolly DC. et al Aorto-coronary saphenous vein bypass surgery: clinical and angiographic results. Mayo Clin Proc 1975; 50: 379-83
• 13 Fuster V, Chesebro JH. Aortocoronary artery vein graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. Circulation 1985; 72 (suppl V) 65-70
• 14 Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary vein graft disease. Circulation 1986; 74: 227-32
• 15 Bode C, Meinhardt G, Runge MS. et al Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84: 805-13
• 16 More RS, Pringle SW, Brack MJ, Gershlick AH. A monoclonal conjugate with powerful antiplatelet and fibrinolytic action that localises to endothelium. Eur Heart J 1992; 13: 265 (abstract)
• 17 Jorgensen B, Bulow J, Jorgensen M. et al Femoral artery recanalisation with percutaneous angioplasty and segmentally enclosed plasminogen activator. Lancet 1989; i: 1106-8
• 18 Meuwissen MW, Minor PL, Beyer GA, Lipchik EO. Symptomatic native arterial occlusions: early experience with “over the wire” thrombolysis. J Vase Interv Radiol 1990; 1: 1106-8
• 19 Underwood MJ, More RS, de Bono DP. The effect of topically applied tissue plasminogen activator on venous fibrinolytic activity in-vitro. Clinical Science 1993; 84: 4 (abstract)
• 20 de Bono DP, Pringe SW. Local inhibition of thrombosis using urokinase linked to a monoclonal antibody which recognises damaged endothelium. Thromb Res 1991; 61: 537-45
• 21 Underwood MJ, Pringle SW, de Bono DP. Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells. Br J Surg 1992; 79: 915-7
• 22 Wolinsky H, Thung SN. Use of a perforation balloon catheter to deliver concentrated heparin into the wall of the normal canine artery.. J Am Coll Cardiol 1990; 15: 475-81